StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories global COVID-19 Testing-Related Sales ($M) ($M)

Global COVID-19 testing sales peaked at $8,368M in FY2022 ($7,677M in FY2021) and declined to $1,590M in FY2023, $747M in FY2024, and $297M in FY2025.

QuarterlyAnnual
Latest, Q4 2025
89
Period ended Dec 31, 2025
Change on a year earlier
-49.4%
176 in Q4 2024
History
19 quarters
Since Q2 2021
Sources
15
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGlobal COVID-19 Testing-Related Sales ($M) ($M)Year on yearSource
Q4 2025Dec 31, 202589-49.4%SEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 202569-74.0%SEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 202555-46.1%SEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 202584-58.8%SEC Filing (0001628280-25-017924) ↗
Q4 2024Dec 31, 2024176-38.9%SEC Filing (0001628280-26-002982) ↗
Q3 2024Sep 30, 2024265-13.1%SEC Filing (0001628280-25-045049) ↗
Q2 2024Jun 30, 2024102-61.2%SEC Filing (0001628280-25-035135) ↗
Q1 2024Mar 31, 2024204-72.1%SEC Filing (0001628280-25-017924) ↗
Q4 2023Dec 31, 2023288-73.1%SEC Filing (0001628280-25-002092) ↗
Q3 2023Sep 30, 2023305-81.7%SEC Filing (0001628280-24-042893) ↗
Q2 2023Jun 30, 2023263-88.7%SEC Filing (0001628280-24-032182) ↗
Q1 2023Mar 31, 2023730-77.9%SEC Filing (0001628280-24-016497) ↗
Q4 2022Dec 31, 20221,069-53.9%SEC Filing (0001628280-24-002009) ↗
Q3 2022Sep 30, 20221,671-12.4%SEC Filing (0001628280-23-034544) ↗
Q2 2022Jun 30, 20222,324+83.4%SEC Filing (0001628280-23-025156) ↗
Q1 2022Mar 31, 20223,304–SEC Filing (0001628280-23-012020) ↗

Breakdown

What makes up global covid-19 testing-related sales ($m)

Cite this data

StockData. (2026). Abbott Laboratories Global COVID-19 Testing-Related Sales ($M) ($M), quarterly Q2 2021–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-covid-tot

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.